ResMed agreed to sell its MatrixCare software business to Frazier Healthcare Partners for $490 million in cash, as it pivots toward sleep, breathing, and home-based care. The deal is a meaningful portfolio reshaping event that could re-rate near-term focus and capital allocation expectations.
ResMed agreed to sell its MatrixCare software business to Frazier Healthcare Partners for $490 million in cash, as it pivots toward sleep, breathing, and home-based care. The deal is a meaningful portfolio reshaping event that could re-rate near-term focus and capital allocation expectations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
